Targeting long non-coding RNAs to treat triple-negative breast cancer
Development of Long non-coding RNA-directed Target Therapy for Triple-Negative Breast Cancer
This study is looking at a new treatment for triple-negative breast cancer by exploring how certain RNA molecules affect the cancer's growth and spread, with the hope of finding a better way to help patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10582619 on NIH RePORTER |
What this research studies
This research focuses on developing a new therapy for triple-negative breast cancer (TNBC), a type of breast cancer that currently lacks effective targeted treatments. The study investigates the role of long non-coding RNAs (lncRNAs) in the cancer's progression and metastasis. By understanding how these RNA molecules influence tumor growth and immune response, the researchers aim to create a targeted therapy that can improve patient outcomes. The approach involves using genetically modified mouse models to explore the mechanisms of lncRNA action and to test potential therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who have limited treatment options.
Not a fit: Patients with other types of breast cancer or those who have already received multiple lines of treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel targeted therapy for patients with triple-negative breast cancer, improving survival rates and treatment options.
How similar studies have performed: While the approach of targeting long non-coding RNAs is relatively novel, there have been preliminary successes in other cancers, suggesting potential for breakthrough advancements in TNBC treatment.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Lin, Chunru — University of Tx Md Anderson Can Ctr
- Study coordinator: Lin, Chunru
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.